Barclays analyst Peter Lawson raised the firm’s price target on Deciphera to $9 from $8 and keeps an Underweight rating on the shares after the company announced preliminary Q4 revenues and new data analysis supporting a potential opportunity in second line gastrointestinal stromal tumors patients. The analyst cites the potential GIST opportunity for the target bump.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DCPH:
